SMNR (Semnur Pharmaceuticals) LT-Debt-to-Total-Asset: 10.78 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMNR Semnur Pharmaceuticals Inc SMNR
10 GF Score
Price $0.55
! 1 Warning Sign
View Full Analysis

What is Semnur Pharmaceuticals LT-Debt-to-Total-Asset?

Semnur Pharmaceuticals SMNR +0.02% 10 LT-Debt-to-Total-Asset is 10.78 as of Jun. 2026. GuruFocus rates SMNR with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Semnur Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 10.78.

Semnur Pharmaceuticals's long-term debt to total assets ratio increased from Jun. 2025 (5.75) to Jun. 2026 (10.78). It may suggest that Semnur Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Semnur Pharmaceuticals  (OTCPK:SMNR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Semnur Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Semnur Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Semnur Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Semnur Pharmaceuticals LT-Debt-to-Total-Asset Chart

Semnur Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
46.46 53.91 7.40 8.86

Semnur Pharmaceuticals Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.75 6.89 8.86 8.59 10.78
SMNR
10GF Score
Semnur Pharmaceuticals Inc SMNR
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Semnur Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Semnur Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=11.928/1.346
=

Semnur Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )/Total Assets (Q: Jun. 2026 )
=20.944/1.943
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 10.78 mean?
Semnur Pharmaceuticals (SMNR) has a LT-Debt-to-Total-Asset of 10.78 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Semnur Pharmaceuticals and its competitors.
Is Semnur Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Semnur Pharmaceuticals' current LT-Debt-to-Total-Asset is 10.78. Overall, Semnur Pharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Semnur Pharmaceuticals' LT-Debt-to-Total-Asset compare to AARD and CBUS?
Semnur Pharmaceuticals' LT-Debt-to-Total-Asset of 10.78 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Semnur Pharmaceuticals and its competitors. Semnur Pharmaceuticals's current LT-Debt-to-Total-Asset is 10.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Semnur Pharmaceuticals stock overvalued right now?
Semnur Pharmaceuticals (SMNR) has a current LT-Debt-to-Total-Asset of 10.78. The current LT-Debt-to-Total-Asset is 10.78. Semnur Pharmaceuticals' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Semnur Pharmaceuticals (SMNR), the current LT-Debt-to-Total-Asset is 10.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Semnur Pharmaceuticals Business Description

Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Semnur Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its main product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), is being developed as a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica), containing no preservatives, surfactants, solvents, or particulates.
10GF Score

Get the complete analysis for SMNR

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.55
Price